ArticleAmerican journal of translational research2024
Changtong paste improves gastrointestinal function of patients after colorectal cancer surgery.
Article in American journal of translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo study the effects of Changtong Paste on gastrointestinal function after colorectal cancer surgery.
methodsA retrospective analysis was conducted on the clinical data of 216 patients who underwent colorectal cancer surgery at the Affiliated Hospital of North Sichuan Medical College from June 2021 to June 2023. Patients were divided into two groups according to their treatment plan: the control group (n=109), who received abdominal multi-source therapy irradiation, and the study group (n=107), who received Changtong Paste in conjunction with the same abdominal irradiation therapy. The two groups were compared in terms of hemorheology, gastrointestinal hormones, immune function, cancer-related fatigue, quality of life, gastrointestinal function, duration of hospital stay, and clinical efficacy.
resultsAfter treatment, both groups demonstrated significant reductions in plasma viscosity, erythrocyte sedimentation rate, high-shear and low-shear whole blood viscosity, somatostatin (SS), vasoactive intestinal peptide (VIP), and scores on the Piper Fatigue Scale-Revised (PFS-R) compared to before treatment, with the study group showing lower levels. Conversely, levels of motilin (MTL), immunoglobulin G (IgG), IgA, IgM, and Quality of Life Questionnaire (QLQ-C30) scores significantly increased after treatment, with the study group showing higher values (P < 0.05). Additionally, indicators for gastrointestinal function recovery and length of hospital stay were shorter in the study group than in the control group (P < 0.05). The total clinical effective rate in the study group (94.39%) was higher than that of the control group (84.40%) (P < 0.05).
conclusionChangtong Paste therapy can effectively regulate hemorheology, improve gastrointestinal hormone levels, promote gastrointestinal and immune function recovery, alleviate cancer-related fatigue, enhance quality of life, and shorten hospital stays after colorectal cancer surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.